Markt geschlossen· · USD · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Investing.com -- The FDA has granted Regenerative Medicine Advanced Therapy designation to Enlivex's experimental immunotherapy Allocetra for age-related knee osteoarthritis, Investing.com has learned.
Enlivex CEO Oren Hershlovitz joined Steve Darling from Proactive to discuss the company’s dual strategy of advancing late-stage clinical drug development while building a digital asset treasury initiative tied to decentralized prediction markets. Hershkovitz explained that Enlivex continues progressing development of Allocetra for osteoarthritis while simultaneously gaining exposure to the growing prediction market sector through the RAIN token ecosystem. The company completed a transformative transaction at the end of 2025 that established a treasury strategy centered around the RAIN protocol
Nes-Ziona, Israel, April 23, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that it will present two poster abstracts at the Osteoarthritis Research Society International (OARSI) 2026 World Congress on Osteoarthritis, taking place April 23-26, 2026, in West Palm Beach, Florida, USA. The presentations will feature 3-month and 6-month endpoints clinical data from the Phase IIa (
We recently compiled a list of the 8 Oversold Biotech Stocks to Invest In Now. Enlivex Ltd. is one of the oversold stocksto invest in now. TheFly reported on April 7 that H.C. Wainwright increased its price target on ENLV from $13 to $20 while maintaining a Buy rating. The firm noted that the company […]
Nes-Ziona, Israel, April 08, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that Ondo Finance (“Ondo”) has launched ENLVon, the Ondo tokenized representation of ENLV’s ordinary shares on Ondo’s Global Markets platform. Through the launch of ENLVon, non-U.S. retail and institutional investors can gain direct economic exposure to Enlivex’s ordinary shares through digital infrast
Enlivex Therapeutics (NASDAQ:ENLV) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline what they described as a “dual-engine” strategy that combines clinical-stage drug development with a digital-asset treasury focused on decentralized prediction markets. Executi
ORLANDO, FL / ACCESS Newswire / March 20, 2026 / RedChip Companies will air interviews with Off The Hook YS Inc. (NYSE American:OTH) and Enlivex Ltd. (NASDAQ:ENLV) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, ...
Enlivex Therapeutics (ENLV) reported that its primary treasury asset, the RAIN token, has been listed on the Kraken cryptocurrency exchange effective February 9, 2026, further expanding access to the token across an additional digital asset trading platform.President's Day Sale - 70% OffUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Published first on TheFl
ORLANDO, FL / ACCESS Newswire / February 9, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays from its Fintech & Digital Asset Treasury ...
ORLANDO, FLORIDA / ACCESS Newswire / January 27, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming Fintech & DATS (Digital Asset Treasury Strategy) ...
Voluntarily Delisting of Ordinary Shares from Trading on the Tel Aviv Stock Exchange to Promote U.S.-Based Trading, Reduce Administrative Costs of Dual Listing Nes-Ziona, Israel, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq and TASE: ENLV) (“Enlivex” or “the Company”), a clinical-stage macrophage reprogramming immunotherapy biotech company and operator of the world’s first prediction markets-focused digital asset treasury centered on RAIN, today announced that it has initi
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.